You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

57 Results
Guidelines and Advice
Status: Current
ID: GL-C50-02
Jan 2012
Guidelines and Advice
Status: Current
ID: GL-C50-29
Mar 2012
Guidelines and Advice
Status: Current
ID: GL 17-10 v2
Version: 2
Mar 2025
Guidelines and Advice
Status: Current
Dec 2012
Guidelines and Advice
Status: Education and Information
Dec 2012
Guidelines and Advice
Status: Current
Mar 2025
Drug
Other Name(s): Iressa®
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2025
Drug
Other Name(s): Jakavi®
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2025
Drug
Other Name(s): Sylvant®
Quick Link(s): Drug Monograph, Patient Info Sheet
Mar 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal DOXOrubicin - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pegylated liposomal DOXOrubicin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Regimen
Cancer Type:
Sarcoma, 
Kaposi's Sarcoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal Doxorubicin - HIV-positive Kaposi's Sarcoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pegylated liposomal DOXOrubicin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
pegylated liposomal DOXOrubicin (Compassionate)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025

Pages